Cyclacel Pharmaceuticals, Inc. (CYCC) |
1.96 0.28 (16.67%) 04-17 16:00 |
Open: | 1.67 |
High: | 2.0899 |
Low: | 1.67 |
Volume: | 113,635 |
Market Cap: | 3(M) |
PE Ratio: | -0.07 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 2.68 |
Resistance 1: | 2.24 |
Pivot price: | 1.99 |
Support 1: | 1.52 |
Support 2: | 1.26 |
52w High: | 13.2 |
52w Low: | 1.52 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
EPS | -25420000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -17.00 |
Return on Assets (ttm) | 290.3 |
Return on Equity (ttm) | -86.3 |
Tue, 16 Apr 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Mon, 01 Apr 2024
Is Cyclacel Pharmaceuticals Inc (CYCC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Tue, 26 Mar 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by StockNews.com to Hold - Defense World
Tue, 19 Mar 2024
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) Profit Outlook - Simply Wall St
Wed, 31 Jan 2024
Cyclacel Pharmaceuticals Announces Chief Medical Officer Termination - TipRanks.com - TipRanks
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |